Pharmacotherapy in Autism and related disorders

School Psychology Quarterly

Volumn 20, Issue 2, 2005, Pages 155-171

  Handen, Benjamin L ^a,b   Lubetsky, Martin ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 22144493808     PISSN: 10453830     EISSN: None     Source Type: Journal    
DOI: 10.1521/scpq.20.2.155.66514     Document Type: Article

References (91)

1. Aman, M. G., Collier-Crespin, A., Lindsay, R. L. (2000). Pharmacotherapy of disorders in mental retardation. European Child and Adolescent Psychiatry, Supplement 1, 198-1107.
2. Aman, M. G., Lam, K. S., & Collier-Crespin, A. (2003). Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders, 33, 527-534.
3. Anderson, L., Campbell, M., Grega, D., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 141, 1195-1202.
4. Antochi, R., Stavrakaki, C., & Emery, P. C. (2003). Psychopharmacological treatments in persons with dual diagnosis of psychiatric disorders and developmental disabilities. Postgraduate Medicine Journal, 9, 139-146.
5. Belsito, K. M., Law, P. A., Kirk, K. S., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. Journal of Autism & Developmental Disorders,. 31, 175-181.
6. Brasic, J. R., Barnett, J. Y., Kaplan, D., Sheitman, B. B., Aisemberg, P., Lafargue, R. T., Kowalik, S., Clark, A., Tsaltas, M. O., & Young, J. G. (1994). Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology, 44, 1309-1312.
7. Campbell, M., Anderson, L., Meier, M., Cohen, I. L., Small, A. M., Samit, C., et al. (1978). A comparison of haloperidol, behavior therapy and their interaction in autistic children. Journal of the American Academy of Child Psychiatry, 17, 640-655.
8. Campbell, M., Anderson, L. T., Small, A. M., Adams, P., Gonzalez, N. M., & Ernst, M. (1993). Naltrexone in autistic children: behavioral symptoms and attentional learning. Journal of the American Academy of Child & Adolescent Psychiatry, 32, 1283-1291.
9. Campbell, M., Armenteros, J., Malone, R. P., Adams, B. P., Eisenberg, Z., & Overall, J. (1997). Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 835-843.
10. Campbell M., Fish B. & David R., (1972) Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. Journal of Autism and Child Schizophrenia, 2, 343-58.
11. Centorrino, F., Albert, M. J., Berry, J. M., Kelleher, J. P., Fellman, V., Line, G., et al. (2003). Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disorder, 5, 370-374.
12. Chabane, N., Leboyer, M., & Mouren-Simeoni, M. C.(2000). Opiate antagonists in children and adolescents. European Child and Adolescent Psychiatry, Supplement 1, 144-150.
13. Childs, J. A., & Blair, J. L. (1997). Valproic acid treatment of epilepsy in autistic twins. Journal of Neuroscience Nursing, 29, 244-248.
14. Cohen, K., Campbell, M., Posner, D., Small, A., Triebel, D., & Anderson, L. T. (1980). Behavioral effects of haloperidol in young autistic children: An objective analysis using a within-subjects reversal design. Journal of the American Academy of Child Psychiatry, 19, 665-677.
15. Cook, E. H. Jr., Rowlett, R., Jaselskis, C., & Leventhal, B. (1992). Fluoxetine treatment of patients with autism and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 739-745.
16. Cook, E. H. Jr., Terry, E. J., Heller, W., & Leventhal, B. L. (1990). Fluoxetine treatment of border-line mentally retarded adults with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 10, 228-229.
17. Curtis, J. L. (1997). Psychotropic medication use in people with developmental disabilities. Maryland Medical Journal, 46, 481-485.
18. Di Martino, A., Melis, G, Cianchetti, C., & Zuddas, A. (2004). Methylphenidate for pervasive developmental disorders: Safety and efficacy of acute single dose test and ongoing therapy: An open-pilot study. Journal of Child and Adolescent Psychopharmacology, 14, 207-218.
19. Eiland, L. S., & Guest, A. L. (2004). Atomoxetine treatment of attention-deficit/hyperactivity disorder. Annals of Pharmacotherapy, 38, 86-90.
20. Fankhauser, M., Marumanchi, V., German, M., Yates, A., & Karumanchi, S. (1992). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry, 53, 77-82.
21. FDA Public Health Advisory, October 15, 2004.
22. Fenichel, G. M. (1997). Clinical pediatric neurology: A signs and symptoms approach. Philadelphia, PA: W.B. Saunders Company.
23. Fukuda, T., Sugie, H., Ito, M., & Sugie, Y. (2001). Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder. No to Hattatsu [Brain & Development], 33, 314-318.
24. Ghaziuddin, M., Tsai, L., & Ghaziuddin, N. (1991). Fluoxetine in autism with depression. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 508-509.
25. Gordon, C. T., Rapoport, J. L., Hamburger, S. D., State, R. C., & Mannheim, G. B. (1992). Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry,. 149, 363-366.
26. Gordon, C. T., State, R., Nelson, J., Hamburger, S., & Rapoport, J. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441-447.
27. Green, W. H. (2001). Child and adolescent clinical psychopharmacology. Philadelphia, PA: Lippincott Williams & Wilkins.
28. Greenhill, L. L., Swanson, J. M., Vitiello, B., Davies, M., Clevenger, W., Wu, M., et al. (2001). Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 180-187.
29. Hamdan-Allen, G. (1991). Brief report: Trichotillomania in an autistic male. Journal of Autism Developmental Disorders, 21, 79-82.
30. Handen, B. L., Feldman, H., Gosling, A., Breaux, A. M., & McAuliffe, S. (1991). Adverse side effects of Ritalin among mentally retarded children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 241-245.
31. Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30, 245-255.
32. Hardan, A., Johnson, K., Johnson C., & Hreczyj, B. (1996). Risperidone treatment of children and adolescents with developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1551-1556.
33. Hellings, J. A. (1999). Psychopharmacology of mood disorders in persons with mental retardation and autism. Mental Retardation and Developmental Disabilities Research Reviews, 5, 270-278.
34. Hellings, J. A., Kelley, L. A., Gabrielli, W. F., Kilgore, E., & Shah, P. (1996). Sertraline response in adults with mental retardation and autistic disorder. Journal of Clinical Psychiatry, 57, 333-336.
35. Hellings, J. A., Zarcone, J. R., Crandall, K., Wallace, D., & Schroeder, S. R. (2001). Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology, 11, 229-38.
36. Hollander, E., Cartwright, C., Wong, C. M., DeCaria, C. M., DelGuidice-Asch, G., Buchsbaum, M. S., et al. (1998). A dimensional approach to the autism spectrum. CNS Spectrum, 3, 22-39.
37. Hollander, E., Dolgoff-Kasper, R., Cartwright, C., Rawitt, R., & Novotny, S.(2001). An open trial of divalproex sodium in autism spectrum disorders. Journal of Clinical Psychiatry, 62, 530-534.
38. Hollander, E., Kaplan, A., Cartwright, C., & Reichman, D. (2000). Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: An open retrospective clinical report. Journal of Child Neurology, 15, 132-135.
39. Holttum, J. R., Lubetsky, M. J., & Eastman, L. E. (1994). Comprehensive management of trichotillomania in a young autistic girl. Journal of the Academy of Child Adolescent Psychiatry, 33, 577-581.
40. Horrigan, J. P., Barnhill, L. J., & Courvoisie, H. E. (1997). Olanzapine in PDD. Journal of the American Academy of Child & Adolescent Psychiatry, 36, 1166-1167.
41. Jaselskis, C. A., Cook, E. H., & Fletcher, K. E. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12, 322-237.
42. Kemner, C., van Engeland, H., & Tuynman-qua, H. (2000). An open-label study of olanzapine in children with PDD. Schizophrenia Research, 41, 194.
43. Kerbeshian, J., Burd, L., & Fisher, W. (1987). Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. Journal of Clinical Psychopharmacology, 7, 401-405.
44. Ketter, T. A., Wang, P. W., Becker, O. V., Nowakowska, C., & Yang, Y. S. (2003). The diverse roles of anticonvulsants in bipolar disorders. Annals of Clinical Psychiatry, 15, 95-108.
45. Komoto, J., Usui, S., & Hirata, J. (1984). Infantile autism and affective disorder. Journal of Autism & Developmental Disorders, 14, 81-84.
46. Koshes, R. J., & Rock, N. L. (1994). Use of clonidine for behavioral control in an adult patient with autism. American Journal of Psychiatry, 151, 1714.
47. Kowatch, R. A., & Bucci, J. P. (1998). Mood stabilizers and anticonvulsants. Pediatric Clinics of North America, 45, 1173-1186.
48. Langworthy-Lam, K. S., Aman, M. G., & Van Bourgondien, M. E. (2002). Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology, 12, 311-322.
49. Madrid, A. L., State, M. W., & King, B. H. (2000). Pharmacologic management of psychiatric and behavioral symptoms in mental retardation. Child and Adolescent Psychiatry Clinics of North America, 9, 225-243.
50. Magen, J. D. (1993). Negative results with clomipramine [Letter]. Journal of ;the American Academy of Child and Adolescent Psychiatry, 32, 1079-1080.
51. Malek-Ahmadi, P., & Simonds, J. F. (1998). Olanzapine for autistic disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 902.
52. Marriage, K. (2002). Schizophrenia and related psychoses. In S. P. Kutcher (Ed.), Practical child and adolescent psychopharmacology (pp. 134-158). Cambridge, United Kingdom: Cambridge University Press.
53. Martin, A., Koenig, K., Scahill, L., & Bregman, J. (1999). Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 9, 99-107.
54. McCracken, J. T., & Martin, W. (1997). Clonidine side effect. Journal of the American Academy of Child & Adolescent Psychiatry. 36, 160-161.
55. McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002). Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314-321.
56. McDougle, C. J. (1998). Efficacy of fluvoxamine in children with autistic disorder. Unpublished manuscript.
57. McDougle, C. J., Brodkin, E. S., Naylor, S. T., Carlson, D.C., Cohen, D. J., & Price, L. H. (1998). Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation. Journal of Clinical Psychopharmacology, 18, 62-66.
58. McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998). A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry, 55, 633-641.
59. McDougle, C. J., Kern, D. L., Posey, D. J. (2002). Case series: use of ziprasidone for maladaptive symptoms in youths with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 921-927.
60. McDougle, C. J., Naylor, T., Cohen, D., Volkmar, F. R., Heninger, G. R., & Price, L. H. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53, 1001-1008.
61. McDougle, C. J., Price, L. H., Volkmar, F. R., Goodman, W. K., Ward-O'Brien, D., Nielsen, J., et al. (1992). Clomipramine in autism: preliminary evidence of efficacy. Journal of the American Academy of Child & Adolescent Psychiatry, 31, 746-750.
62. Mehlinger, R., Scheftner, W. A., & Poznanski, E. (1990). Fluoxetine and autism. Journal of the American Academy of Child and Adolescent Psychiatry, 29, 985.
63. Malek-Ahmadi, P., & Simonds, J. F. (1998). Olanzapine for autistic disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 902.
64. Namerow, L. B., Thomas, P., Bostic, J., Prince, J., & Monuteaux, M. (2003). Use of citalopram in pervasive developmental disorders. Developmental and Behavioral Pediatrics, 24, 104-108.
65. National Institutes of Health (2004). Medlineplus website. Washington, DC.
66. Nicholas, R., Awad, B., & Sloman, L. (1998). An open label trial of risperidone in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 372-376.
67. Ozbayrak, K. (1997). Sertraline in PDD. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 7-8.
68. Peral, M., Alcami, M., & Gilaberte, I. (1999). Fluoxetine in children with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 1472-1473.
69. Physicians' Desk Reference. (2004). Oradell, NJ: Medical Economics Co.
70. Plioplys, A. V. (1994). Autism: electroencephalogram abnormalities and clinical improvement with valproic acid. Archives of Pediatrics & Adolescent Medicine, 148, 220-222.
71. Posey, D. I., Litwiller, M., Koburn, A., & McDougle, C. J. (1999). Paroxetine in autism. Letter] Journal of the American Academy of Child and Adolescent Psychiatry, 38, 111-112.
72. Posey, D. J., & McDougle, C. J., (2003). Use of atypical antipsychotics in autism. In E. Hollander (Ed.), Autism spectrum disorders (pp. 247-264). New York: Marcel Dekker, Inc.
73. Posey, D. J., Puntney, J. I., Sasher, T. M., Kern, D. L., Kohn, A., & McDougle, C. J. (2004). Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. Journal of Child and Adolescent Psychopharmacology, 14, 233-242.
74. Potenza, M. N., Holmes, J. P., Kanes, S. J., & McDougle, C. J., (1999). Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. Journal of Clinical Psychopharmacology, 19, 31-44.
75. Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., et al. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders, 25, 283-294.
76. Rubin, M. (1997). Use of atypical antipyschotics in children with mental retardation, autism, and other developmental disabilities. Psychiatry Annals, 27, 219-221.
77. Rugino, T. A., & Samsock, T. C. (2002). Levetiracetam in autistic children: An open-label study. Journal of Developmental & Behavioral Pediatrics, 23, 225-230.
78. Sanchez, L. E., Campbell, M., Small, A. M., Cueva, J. E., Armenteros, J. L., & Adams, P. B. (1996). A pilot study of clomipramine in young autistic children. Journal of the American Academy of Child & and Adolescent Psychiatry, 35, 537-544.
79. Santosh, P. J., & Baird, G. (1999). Psychopharmacotherapy in children and adults with intellectual disability. Lancet, 354, 233-242.
80. Schou, M. (2001). Lithium treatment at 52. Journal of Affective Disorders, 67, 21-32.
81. Snead, B. W., Boon, F., & Presberg, J. (1994). Paroxetine for self-injurious behavior. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 909-910.
82. Spencer, T., Heiligenstein, J., Biederman, J., Fanes, D. E., Kratochvil, C. J., Conners, C. K., et al. (2002). Results From 2 Proof-of-Concept, Placebo-Controlled Studies of Atomoxetine in Children with Attention-Deficit/ Hyperactivity Disorder. Journal of Clinical Psychiatry, 63, 1140-1147.
83. Staller, J. A. (2003). Aripiprazole in an adult with Asperger disorder. Annals of Pharmacotherapy, 37, 1628-1631.
84. Steingard, R., & Biederman, J. (1987). Lithium responsive manic-like symptoms in two individuals with autism and mental retardation. Journal of the American Academy of Child & Adolescent Psychiatry, 26, 932-935.
85. Steingard, R. J., Zimnitzky, B., DeMaso, D. R., Bauman, M. L., & Bucci, J. P. (1997). Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 7, 9-15.
86. Todd, R. D. (1991). Fluoxetine in autism. American Journal of Psychiatry 148, 1089.
87. vebrant, P., & Usui, S. (1994). Intractable epilepsy in children: The efficacy of lamotrigine treatment, including non-seizure related benefits. Neuropediatrics, 25, 284-289.
88. Van Bellinghen, M., & De Troch, C. (2001). Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology, 11, 5-13.
89. Willemsen-Swinkels, S. H., Buitelaar, J. K., Nijhof, G. J., & van England, H. (1995). Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Archives of General Psychiatry, 52, 766-773.
90. Yokoyama, H., Hirose, M., Haginoya, K., Munakata, M., & Iinuma, K. (2002). Treatment with flu-voxamine against self-injury and aggressive behavior in autistic children. No to Hattatsu [Brain & Development], 34, 249-253.
91. Zuddas. A., Ledda, M. G., Fratta, A., Muglia, P., & Cianchetti, C. (1996). Clinical effects of clozapine on autistic disorder. American Journal of Psychiatry, 153, 738.